# Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

> **NCT06487078** · NA · RECRUITING · sponsor: **Pfizer** · enrollment: 90 (estimated)

## Conditions studied

- ALK+ Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06487078
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06487078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06487078, "Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06487078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*